Feature | ESC | September 07, 2017

Oxygen Therapy Does Not Improve Survival in Heart Attack Patients

Results of the DETO2X-AMI study show room air equal to oxygen in outcomes

Giving oxygen to patients suffering a heart attack is not beneficial, according to the DETO2X-AMI study.

Giving oxygen to patients suffering a heart attack is not beneficial, according to the DETO2X-AMI study presented at ESC 2017.

September 7, 2017 — Oxygen therapy does not improve survival in patients with heart attack symptoms, according to late-breaking research from the DETO2X-AMI Study presented in a Hot Line session at the European Society of Cardiology (ESC) Congress and published in the New England Journal of Medicine (NEJM).

“The DETO2X-AMI study questions the current practice of routine oxygen therapy for all patients with suspected myocardial infarction,” said first author Dr Robin Hofmann, a cardiologist from the Karolinska Institutet at Södersjukhuset, Stockholm, Sweden.

This prospective, randomized, open-label trial enrolled 6,229 patients with suspected heart attack from 35 hospitals across Sweden. Half of the patients were assigned to oxygen given through an open face mask and the other half to room air without a mask.

The primary outcome, the mortality rate one year after randomization, was not statistically different between the two groups (5% in the oxygen group versus 5.1% in the air group). Similarly, there was no significant difference between the two groups for secondary endpoints, including the risk of a new heart attack or heart muscle injury measured by markers in the blood.

Even in patients at high risk, such as smokers, older patients, patients with diabetes, or patients with previous heart disease, the results were similar concerning mortality within one year.

European Society of Cardiology (ESC) guidelines on treatment of patients with ST-segment elevation myocardial infarction (STEMI) recommend oxygen (by mask or nasal prongs) for patients who are breathless, hypoxic, or have heart failure. They add that the systematic use of oxygen in patients without heart failure or dyspnoea (shortness of breath) “is at best uncertain”.

“ESC guidelines have gradually shifted towards more restrictive use of oxygen,” said author Prof. Stefan James, a cardiologist at Uppsala University, Uppsala, Sweden. “While the current recommendations were based on expert opinion only, we can now add substantial new data from our large clinical trial.”

“The study results will likely have an immediate impact on clinical practice and future guidelines,” he added. “Our findings do not support the routine use of oxygen therapy in all patients with symptoms of a heart attack. The general use of oxygen in these cases is still widespread in the world but can now be adjusted.”

A fear that oxygen therapy could be harmful arose after the AVOID trial found a larger infarct size in patients receiving oxygen therapy. “Routine oxygen therapy seems unnecessary in this patient group, but fortunately our data do not give any indication of increased risk for the patients on oxygen,” said Prof. James. “So all of us who have generally used oxygen for decades can now rest assured.”

The DETO2X-AMI trial is the first large-scale randomized trial of oxygen therapy in patients with suspected myocardial infarction to be large enough to reveal meaningful findings on mortality and morbidity. The study enrolled six times more patients than all previous randomized trials of this therapy combined and included a much broader range of patients to make the results relevant to everyday clinical practice.

The study’s registry-based randomized clinical trial protocol used national registries including SWEDEHEART for randomization, case record forms and follow-up. Dr Hofmann said: “With this design we could enrol 6 629 patients with high quality data in less than three years and keep overall costs to a fraction of a conventional randomized trial.”

Read about other late-breakers in the article “Late-breaking Trial Presentations at ESC 2017.”
 

References:

1. Robin Hofmann, Stefan K. James, Tomas Jernberg, et al. “Oxygen Therapy in Suspected Acute Myocardial Infarction.” NEJM. Published online Aug. 28, 2017.

2. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. European Heart Journal. 2012;33:2569–2619. doi:10.1093/eurheartj/ehs215.

3. Stub D, et al. Air versus oxygen in ST-segment-elevation myocardial infarction. Circulation. 2015;131:2143–2150. doi: 10.1161/CIRCULATIONAHA.114.014494.

Related Content

New Oral Anticoagulant Drugs Associated with Lower Kidney Risks
News | Antiplatelet and Anticoagulation Therapies| December 12, 2017
Mayo Clinic researchers have shown a link between which type of oral anticoagulant a patient takes to prevent a stroke...
CorInnova Awarded 2017 InnoSTARS Prize for EpicHeart Soft Robotic Heart Assist Device
News | Artificial Heart| December 11, 2017
CorInnova Inc. recently announced it was awarded second prize in the “2017 InnoSTARS” life science competition for its...
ECG Study of NBA Players Shows Need for Sport-Specific Normative Data and Guidelines
News | ECG| December 08, 2017
Cardiologists at NewYork-Presbyterian/Columbia University Irving Medical Center compared electrocardiographic findings...
New Study Suggests Protein Could Protect Against Coronary Artery Disease

Patients with no obstructed blood flow in the coronary arteries had higher levels of CXCL5 (blue) compared to patients with moderate levels (green) or lower levels (yellow) of CXCL5, who had increased severity of coronary obstructions (indicated by the arrows). Credit: Schisler lab

News | Cardiac Diagnostics| December 07, 2017
December 7, 2017 — The buildup of plaque in the heart’s arteries is an unfortunate part of aging.
Edwards Acquires Harpoon Medical
News | Heart Valve Technology| December 07, 2017
December 7, 2017 — Edwards Lifesciences Corp.
Robocath Receives $1.5 Million in Capital for Advancement of R-One Robotic System
News | Robotic Systems| December 06, 2017
December 6, 2017 — French company Robocath, which designs and develops...
New data on the Corvia intra-atrial shunt to treat diastolic heart failure were presented at the recent 2017 American Heart Association (AHA) Scientific Sessions. It was the most popular story in November.

New data on the Corvia intra-atrial shunt to treat diastolic heart failure were presented at the recent 2017 American Heart Association (AHA) Scientific Sessions. It was the most popular story in November.

Feature | December 06, 2017 | Dave Fornell
Here is the list of the most popular articles and videos on the Diagnostic and Interventional Cardiology (DAIC) magaz
New Tool Predicts Risk of Heart Attack in Older Surgery Patients
News | Cardiac Diagnostics| December 05, 2017
A tool designed to more accurately predict the risk of heart attack in older patients undergoing non-cardiac surgery...
Screening for Critical Congenital Heart Disease at Birth Saves Lives
News | Congenital Heart| December 05, 2017
Infant deaths from critical congenital heart disease (CCHD) decreased more than 33 percent in eight states that...
Toshiba Medical Rolls Out Interactive Learning Tools for Ultrasound and Vascular Training
News | Ultrasound Imaging| December 04, 2017
Toshiba Medical, a Canon Group company, introduced new educational tools and interactive learning resources to help...
Overlay Init